Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for RLAY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 -54.11M
March 31, 2026 -51.11M
December 31, 2025 -44.86M
September 30, 2025 -62.12M
June 30, 2025 -55.26M
March 31, 2025 -73.21M
December 31, 2024 -57.87M
September 30, 2024 -75.08M
June 30, 2024 -65.83M
March 31, 2024 -50.32M
December 31, 2023 -89.19M
September 30, 2023 -75.40M
June 30, 2023 -68.60M
March 31, 2023 -67.13M
December 31, 2022 -57.08M
Date Value
September 30, 2022 -66.14M
June 30, 2022 -57.09M
March 31, 2022 -49.17M
December 31, 2021 -39.71M
September 30, 2021 -53.20M
June 30, 2021 -28.14M
March 31, 2021 46.64M
December 31, 2020 -35.27M
September 30, 2020 -24.04M
June 30, 2020 -20.84M
March 31, 2020 -22.33M
December 31, 2019 -22.76M
September 30, 2019 -17.50M
June 30, 2019 -15.05M
March 31, 2019 -10.82M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
AbbVie, Inc. 3.436B
TG Therapeutics, Inc. 39.26M
Karyopharm Therapeutics, Inc. -24.93M
Krystal Biotech, Inc. 74.79M
Akebia Therapeutics, Inc. 3.525M